

According to him, this is a great result for patients, who will benefit from improved access to more medicines with higher

therapeutic value.

“Partnering with a leading company like Mundipharma is of real value and importance to NTC as it confirms the importance of our development efforts in the ophthalmic area,” said Riccardo Carbucicchio, President and CEO, NTC.

“Mundipharma are an ideal strategic partner in the Middle East and Africa with the capability and expertise to extend the reach of these medicines to benefit more patients,” he added